Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair

Small cell lung cancer (SCLC) is frequently found disseminated at first presentation and holds a poor prognosis due to emerging resistance to first-line platinum-based and second-line topotecan chemotherapy. The present investigation tested the antitumor activity of rovalpituzumab tesirine (ROVA-T), a cytotoxic anti-DLL3 drug conjugate, against two SCLC and a corresponding SCLC CTC cell line established from a ROVA-T-resistant patient to characterize the mechanism of recurrence. Two cell lines were established from an SCLC patient progressing under ROVA-T therapy and characterized with respect to chemosensitivity against this drug as well as against currently applied chemotherapeutics and for their delta-like 3 (DLL3) expression. The chemosensitivity assays demonstrate that most SCLC lines show IC50 values exceeding the ROVA-T in-vivo concentrations and that slow-growing cells and lines showing spheroidal growth or proliferation as corresponding circulating tumor cells (CTCs) exhibit higher resistance. Chemosensitivity of the cell lines is not correlated with DLL3 protein expression possibly due to toxicity of the free payload in tissue culture. The clinical trials and experimental results demonstrate that refractoriness to ROVA-T is linked to a low initial tumor expression of DLL3, loss of DLL3 expression, higher chemoresistance to ROVA-T and the putative formation of resistant spheroids by the SCLC cells.

[1]  M. Tiemann,et al.  Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples , 2021, Frontiers in Medicine.

[2]  A. Adjei,et al.  All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Tomohito Tanaka,et al.  Delta‐like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview , 2021, Cancer science.

[4]  Melissa L. Johnson,et al.  A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC , 2021 .

[5]  T. Burns,et al.  A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC , 2021 .

[6]  K. Nackaerts,et al.  Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study , 2021 .

[7]  G. Stark,et al.  CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer , 2020, British Journal of Cancer.

[8]  E. Lobenhofer,et al.  AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer , 2020, Clinical Cancer Research.

[9]  Zhaomei Zhang,et al.  Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression , 2020, Translational oncology.

[10]  A. Chiappori,et al.  Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC) , 2020, Frontiers in Oncology.

[11]  Xiaoqing Yang,et al.  Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth , 2020, Journal for immunotherapy of cancer.

[12]  Stephen V. Liu,et al.  Drugs in development for small cell lung cancer , 2020, Journal of thoracic disease.

[13]  M. Krasnow,et al.  New Approaches to SCLC Therapy: From the Laboratory to the Clinic , 2020 .

[14]  Asher Mullard.  Cancer stem cell candidate Rova-T discontinued , 2019, Nature Reviews Drug Discovery.

[15]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[16]  I. Okamoto,et al.  Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. , 2019, Lung cancer.

[17]  E. Obermayr,et al.  Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer , 2019, Cells.

[18]  P. Nana-Sinkam,et al.  Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer , 2019, Respiration.

[19]  M. Nishimura,et al.  Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702). , 2019, The oncologist.

[20]  E. Giovannetti,et al.  Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges , 2019, Cellular Oncology.

[21]  O. Burghuber,et al.  Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  B. Bossenmaier,et al.  Acquired Resistance to Antibody-Drug Conjugates , 2019, Cancers.

[23]  M. Hamid,et al.  Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate , 2018, Drugs in R&D.

[24]  J. Hartley,et al.  Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine , 2018, Scientific Reports.

[25]  Y. Nakanishi,et al.  Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. , 2018, Lung cancer.

[26]  C. Rudin,et al.  Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. , 2017, Cancer research.

[27]  R. Zeillinger,et al.  Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance , 2017, Scientific Reports.

[28]  J. Aster,et al.  The Varied Roles of Notch in Cancer. , 2017, Annual review of pathology.

[29]  Li Wang,et al.  The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice. , 2017, Biochemical and biophysical research communications.

[30]  H. Ohmatsu,et al.  Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy. , 2016, Clinical lung cancer.

[31]  de Goeij,et al.  Antibody-drug conjugates in cancer , 2016 .

[32]  C. Rudin,et al.  Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study , 2016 .

[33]  C. Rudin,et al.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.

[34]  R. Zeillinger,et al.  Circulating Tumor Cells in Small Cell Lung Cancer: Ex Vivo Expansion , 2015, Lung.

[35]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.